After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars in sales this year, one group of analysts pr
After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars in sales this year, one group of analysts pr